Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease

Harsh Agrawal, Kul Aggarwal, Rachel Littrell, Poonam Velagapudi, Mohit K. Turagam*, Mayank Mittal and Martin A. Alpert

Division of Cardiovascular Medicine, University of Missouri-Columbia, School of Medicine, Columbia, MO, USA

Abstract: Patients with advanced chronic kidney disease (CKD), including those treated with dialysis, are at high risk for the development of cardiovascular disease (CVD). CVD accounts for 45-50% of deaths among dialysis patients. Therapy of acute and chronic coronary heart disease (CHD) that is effective in the general population is frequently less effective in patients with advanced CKD. Drug therapy in such patients may require dose modification in some cases. Oral anti-platelet drugs are less effective in those with advanced CKD than in persons with normal or near normal renal function. The intravenous antiplatelet drugs epifibatide and tirofiban both require dose reductions in patients with advanced CKD. Enoxaparin requires dose reduction in early stage CKD and is contraindicated in hemodialysis patients. Unfractionated heparin and warfarin may be used without dose adjustment in CKD patients. Atenolol, acetbutolol and nadolol may require dose adjustments in CKD. Metoprolol and carvedilol do not. Calcium channel blockers and nitrates do not require dose adjustment, whereas ranolazine does. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers may safely be used in CKD patients with close observation for hyperkalemia. The safety of spironolactone in such patients is questionable. Statins are less effective in reducing cardiovascular complication in CKD patients and their initiation is not recommended in dialysis patients. Coronary artery bypass grafting is associated with higher short-term mortality, but better long-term morbidity and mortality than percutaneous coronary interventions in patients with advanced CKD with non-ST segment ACS and chronic CHD.

Keywords: Chronic kidney disease, end-stage renal disease, dialysis and hemodialysis, acute coronary syndrome, chronic coronary heart disease, pharmacotherapy, myocardial revascularization.

INTRODUCTION

Coronary heart disease (CHD) occurs commonly in patients with chronic kidney disease (CKD), particularly in those with end-stage renal disease (ESRD) treated with dialysis [1-20]. In the HEMO study nearly 40% of the 1,846 patients entered had ischemic heart disease on entering the study [9]. During the mean follow-up period of 2.8 years angina pectoris and acute myocardial infarction caused 43% of all cardiac hospitalizations. The United States Renal Data System (USRDS) surveys suggest that the annual rate of myocardial infarction and/or angina pectoris in dialysis patients is approximately 10% [10]. In a study by Parekh et al. the incidence of new onset atherosclerosis (predominantly CHD) was 147/1000 patient years in Caucasians and 119/1000 patient years in African-Americans in the United States [11]. Occult or silent-myocardial ischemia occurs commonly in dialysis patients. Ohtake and colleagues reported >50% stenosis of at least one coronary artery in 16 of 30 asymptomatic patients receiving renal replacement therapy [12]. Charytan and co-workers reported ≥50% stenosis of at least one coronary artery in 28 of 67 asymptomatic patients receiving dialysis, 19 of whom had high-grade proximal stenosis [13]. Conlon et al. reported evidence of dynamic ST segment depression or ambulatory electrocardiographic monitoring in 16 of 67 asymptomatic dialysis patients suggesting silent myocardial ischemia [14]. In a Canadian multicenter study involving 432 patients beginning dialysis who were followed for a mean duration of 41 months, cardiac and vascular disease was common [15]. Myocardial infarction or unstable angina pectoris occurred in 15%, stable angina pectoris occurred in 19%, heart failure occurred in 31%, arrhythmias occurred in 7% and peripheral arterial disease occurred in 8% [15]. The USRDS Wave II Dialysis Morbidity and Mortality Study reported an incidence of acute coronary syndrome (ACS) of 2.9% per year among 3329 incident dialysis patients followed for two years [16]. USRDS data from 1998-2000 demonstrated that among dialysis patients in the United States, the death rate was 23.6% per year with cardiac disease accounting for 45% of deaths [10]. Myocardial infarction accounted for 20% of cardiac deaths and sudden cardiac arrest accounted for 60% of cardiac deaths. Subsequent studies have shown a similar distribution of causes of death in dialysis patients [17-20]. Thus, cardiovascular disease (CVD) accounts for 45-50% of deaths in patients receiving dialysis. The mortality risk is 10-20 times higher in dialysis patients than in the patients from the general population.
matched for age, gender and race [17-20]. In younger patients receiving renal replacement therapy the risk of death from CVD approaches 100 times that at the age-matched population [20]. In a study of 34,198 HD patients cardiac mortality after acute myocardial infarction was 40.8% at one year, 51.8% at two years and 70.2% at five years [16]. Among patients with coronary artery disease detected on coronary angiography, the incidence of multi-vessel disease is significantly higher in hemodialysis (HD) patients than in non-HD patients (87% vs. 62%, p <0.05) as is the incidence of calcified lesions (81% vs. 37%, p <0.05) [20]. CHD may present acutely (ACS, sudden cardiac arrest) or chronically (stable angina pectoris, silent myocardial ischemia, ischemic cardiomyopathy). During the past 35 years numerous therapeutic modalities have been developed to treat acute and chronic CHD and have been successful in reducing morbidity and mortality in such patients in the general population [21, 22]. However, the pathophysiology and natural history of CHD in patients with advanced CKD (particularly treated with HD) differs in many respects from that in the general population [23-26]. Many therapeutic modalities that are effective in treating CHD in the general population are not as effective in patients with advanced CKD (stages 4-6) [23-27]. The purpose of this review is to discuss the efficacy and safety of pharmacologic and non-pharmacologic therapies used to treat acute and chronic CHD in patients with advanced CKD with special emphasis on those receiving HD, and to provide recommendations concerning the use of these modalities in such patients.

PHARMACOTHERAPY

Oral Anti-Platelet Drugs

Oral anti-platelet drugs are employed routinely in patients with ACS and in those with chronic CHD [21, 22, 27]. Oral anti-platelet drugs used in CHD include aspirin, clopidogrel, prasugrel and ticagrelor [21, 22].

Aspirin has been shown to reduce short and long-term CV mortality and morbidity in patients with ACS and in those with chronic CHD in the general population [21, 22, 28-30]. Clinical trials specifically assessing the effect of aspirin on CV morbidity or mortality in HD patients are lacking; however, several studies have assessed the effect of aspirin on CV outcomes in patients with CKD and CVD [28-30]. In a post-hoc analysis of the Hypertension Optimal Treatment Trial by Gum et al. which included 18,597 patients with an estimated glomerular filtration rate (eGFR) <45 ml/min/1.73m² and who received aspirin 75 mg orally daily had significant reductions in major cardiac events (RR: 0.66, 95% CI: 0.33-0.83, p=0.03) and total mortality (RR: 0.49, 95% CI: 0.06-0.73, p=0.04) compared to those with an eGFR ≥45 ml/min/1.73m² [2, 30]. There was a non-significant trend towards increased bleeding in the group receiving aspirin. In a meta-analysis of 50 studies comprising 27,139 patients with CKD of any stage (including 4820 dialysis patients) Palmer and colleagues showed that the risk of fatal and non-fatal myocardial infarction was significantly reduced in patients treated with oral anti-platelet drugs compared to those not treated with oral anti-platelet therapy (RR: 0.66, 95% CI: 0.51-0.87); however, there was no significant effect on total mortality [31]. A beneficial effect of oral anti-platelet therapy was not observed in the HD subgroup which may be attributable to lack of statistical power (non-HD patients outnumbered HD patients by a factor of 3.8) [31]. Aspirin was the most common anti-platelet drug used in this study. No dose adjustments (Table I) in aspirin are required in patients with CKD although close observation for gastrointestinal bleeding is advised.

Clopidogrel is a first generation thienopyridine that inhibits ADP-related platelet activation. It has been shown to be less effective in patients with than in those without CKD [31-34]. This may be attributable to reduced ADP-related glycoprotein IIb/IIIa receptor exposure leading to less platelet aggregation, increased platelet turnover, or impaired clopidogrel absorption. In a post-hoc analysis of the CREDO trial by Best and co-workers patients with mild to moderate CKD who received clopidogrel demonstrated no significant reduction in cardiovascular events at one year [34]. No dose adjustment is required in CKD patients receiving clopidogrel.

Prasugrel is a third generation oral thienopyridine P2Y12 receptor antagonist [31, 35]. It has a more rapid time to peak effect than clopidogrel. In the TRITON-TIMI 38 trial prasugrel was more effective than clopidogrel in reducing cardiovascular events in patients with CKD [30, 35]. No information exists concerning the efficiency of prasugrel in HD patients. Prasugrel’s active metabolite levels are reduced by 40% in ESRD, although the degree of platelet inhibition is similar to that of patients with normal renal function [30, 35]. For this reason no dose adjustment is required in patients with CKD receiving prasugrel. Bleeding risk is higher in patients receiving prasugrel than in those receiving clopidogrel in patients with and without CKD [30, 35].

Ticagrelor is a reversible P2Y12 receptor antagonist. Like prasugrel, ticagrelor produces a more effective anti-platelet effect than clopidogrel [30, 36, 37]. In the PLATO trial ticagrelor significantly reduced the primary composite endpoint of CV death, myocardial infarction and stroke at 12 months compared to clopidogrel in patients with ACS [36]. In this study patients receiving ticagrelor did not have more major bleeding, but did have more procedure-related bleeding than those receiving clopidogrel [36]. Ticagrelor is cleared through the liver and doesn’t require a dose adjustment in patients with CKD including those with ESRD [36].

Intravenous Anti-Platelet Drugs

Multiple randomized clinical trials in the general population have shown a reduction in major adverse CV events with the addition of intravenous glycoprotein IIb/IIIa receptor antagonists to standard therapy of ACS, particularly in those receiving PCI [21, 22, 38-40]. Glycoprotein IIb/IIIa receptor antagonists used in these studies include abciximab, eptifibatide and tirofiban [21, 22, 38-40]. In a study of 889 patients with ACS, 312 were noted to have varying degrees of CKD. After adjustment for creatinine clearance intravenous glycoprotein IIb/IIIa receptor antagonist therapy was associated with reduced in-hospital mortality (adjusted OR:0.34, 95% CI:0.12-0.98, p<0.04) [40]. For patients with CKD undergoing PCI, abciximab does not require dose adjustment in patients with CKD as it is metabolized by the liver. Eptifibatide requires a 50% dose reduction in patients...
Coronary Heart Disease in Chronic Kidney Disease

Table 1. Dose adjustments for drugs used in CKD in patients with acute or chronic CHD.

| Drug                      | Dose Adjustment In CKD/Dialysis                      |
|---------------------------|------------------------------------------------------|
| Aspirin                   | None                                                 |
| Clopidogrel               | None                                                 |
| Prasugrel                 | None                                                 |
| Ticagrelor                | None                                                 |
| Abciximab                 | None                                                 |
| Eptifibatide              | 50% dose reduction with a creatinine clearance <50 ml/min |
| Tirofiban                 | 50% dose reduction with a creatinine clearance <30 ml/min |
| Unfractionated heparin    | None                                                 |
| Enoxaparin                | Reduce by 50% with CKD; contra-indicated in dialysis patients |
| Warfarin                  | None                                                 |
| Bivalrudin                | No specific guidelines                               |
| Fondaparinux              | No specific guidelines                               |
| Fibrinolytics             | No specific guidelines                               |
| Beta-and alpha/beta-blockers | None required for metoprolol or carvedilol; possible dose reduction for atenolol, acebutalol and nadolol |
| Calcium channel blockers  | None required                                         |
| Nitrates                  | None required                                         |
| Ranolazine                | Dose reduction required                               |
| ACE inhibitors            | Initiate low dose and increase as tolerated; observe for deterioration of renal function and hyperkalemia |
| Angiotensin receptor blockers | Initiate low dose and increase as tolerated; observe for deterioration of renal functions and hyperkalemia |
| Aldosterone receptor blockers | Safety not well-established in advanced CKD           |
| Statins                   | No dose adjustment required; efficiency not well-established in dialysis patients |

Abbreviations: CKD = chronic kidney disease, CHD = chronic heart disease, qd = once per day, bid = twice per day, IV = intravenous, SQ = subcutaneous, ACE = angiotensin converting enzyme

with a creatinine clearance <50 ml/min [40]. Tirofiban requires a 50% dose reduction in those with a creatinine clearance <30 ml/min [38, 41, 42]. Neither eptifibatide nor tirofiban should be used in patients on HD as they are both associated with a greater risk of bleeding in such patients compared to abciximab [40, 41].

Anticoagulant Therapy

Anticoagulants are used most commonly to treat CHD in patients with or without CKD who have developed ACS [21, 22, 41-45]. In the general population intravenous infusion of unfractionated heparin and subcutaneous enoxaparin have received IA recommendations from the American Heart Association and American College of Cardiology as adjunctive therapy for STEMI, NSTEMI and unstable angina pectoris [21, 22]. Bivalrudin (a direct anti-thrombin drug) has received an IB recommendation [21, 22]. Unfractionated heparin may be used safely in all classes of CKD (including HD patients) without dose adjustment [21, 22, 41, 42, 44]. The dose of enoxaparin should be reduced by 50% in patients with CKD and is contra-indicated in HD patients as it is, to a large extent, metabolized by the kidney [41, 43, 44]. No data are available concerning the safety and efficacy of bivalrudin in CKD patients with ACS. Bivalrudin is cleared by the kidney and is dialyzable. In the ACUITY trial which compared bivalrudin with other anti-coagulant/anti-platelet strategies, patients with non-ST segment ACS and a creatinine clearance <30 ml/min were excluded [45]. No data exists on the safety and efficacy of fondaparinux (a factor Xa inhibitor) in patients with advanced CKD and ACS. There are no formal criteria or dose modification guidelines for the use of fibrinolytic agents including streptokinase, alteplase, reteplase lanetaplase and tenteecteplase in STEMI patients with advanced CKD including those receiving HD [21, 22].

At one time, warfarin was used as a substitute for aspirin following acute myocardial infarction in aspirin-intolerant or aspirin allergic patients. With the advent of multiple oral anti-platelet drugs, this is no longer necessary. Warfarin is used primary for left ventricular thrombus or in patients with atrial fibrillation who develop ACS [21, 22]. Current guidelines suggest that if warfarin is to be used in patients receiving dual antiplatelet therapy that the target INR should be 2.0-2.5. Newer oral anticoagulant drugs including dabiga-
Patients who have suffered STEMI or NSTEMI and whose blockers (ARB’s) in patients in the general population in converting enzyme (ACE) inhibitors or angiotensin receptor blockers may be safely used to treat chronic stable angina pectoris in patients with CKD. Among 11,142 patients in the 2012 USRDS registry, 8.5% received beta-blockers. Their use was associated a lower adjusted mortality rate (HR: 0.72, 95% CI: 0.66-0.79, p<0.0001). The extent to which this occurred in patients with CHD or following myocardial infarction is uncertain. Both selective and non-selective beta-blockers have been shown to reduce CV events in patients with CKD and heart failure [49-52]. Carvedilol is cleared by the liver and does not require dose adjustment in CKD. Atenolol, acebutalol and nadolol undergo renal clearance and may require dose adjustment in patients receiving dialysis [49-52].

In the general population, first generation calcium channel blockers are commonly used to treat stable angina pectoris in the absence of moderate to severe left ventricular systolic dysfunction [51, 53]. Among second generation calcium channel blockers, amlodipine and nicardipine may be safely used for this purpose independent of left ventricular systolic function [51, 53]. First generation calcium channel blockers are generally avoided after ACS. Second generation calcium channel blockers may be safely used to treat hypertension in such patients [51, 53]. There are no studies assessing, the role of calcium channel blockers in patients with CKD and ACS. Second generation dihydropyridine calcium channel blockers may be safely used to treat chronic stable angina pectoris in patients with CKD [51, 53]. Diltiazem and verapamil may be used in such patients in the absence of moderate to severe left ventricular systolic dysfunction.

Sublingual nitroglycerin and long-acting oral nitrates are hepatically-metabolized. They may be used safely in patients with CKD including those receiving HD.

Ranolazine blocks inward sodium channels and has been shown to reduce the frequency of stable angina pectoris in patients with chronic CHD with no effect on hemodynamics [54, 55]. The drug is 70% cleared by the kidney [54]. In the MERLIN TIMI-36 trial, it failed to reduce cardiovascular events in patients with NSTEMI [55]. It may be considered as a fourth line drug for chronic stable angina pectoris with dose modification in patients with CKD.

Anti-ischemic Drug Therapy

In the general population, most, but not all studies assessing the effect of beta-and alpha/beta-adrenergic blocking agents (metoprolol, bisoprolol, carvedilol) in acute myocardial infarction have demonstrated improved survival, reduced risk for sudden cardiac death and a decrease in recurrence in patients who treated with these drugs [21, 22]. There are no studies specifically assessing the effect of blockers or alpha/beta blockers on prognosis after acute myocardial infarction in patients with CKD. However, indirect evidence suggests that such agents may improve mortality in patients with advanced CKD. Among 11,142 patients in the 2012 USRDS registry, 8.5% received beta-blockers. Their use was associated a lower adjusted mortality rate (HR: 0.72, 95% CI: 0.66-0.79, p<0.0001). The extent to which this occurred in patients with CHD or following myocardial infarction is uncertain. Both selective and non-selective beta-blockers have been shown to reduce CV events in patients with CKD and heart failure [49-52]. Carvedilol is cleared by the liver and does not require dose adjustment in CKD. Atenolol, acebutalol and nadolol undergo renal clearance and may require dose adjustment in patients receiving dialysis [49-52].

In the general population, first generation calcium channel blockers are commonly used to treat stable angina pectoris in the absence of moderate to severe left ventricular systolic dysfunction [51, 53]. Among second generation calcium channel blockers, amlodipine and nicardipine may be safely used for this purpose independent of left ventricular systolic function [51, 53]. First generation calcium channel blockers are generally avoided after ACS. Second generation calcium channel blockers may be safely used to treat hypertension in such patients [51, 53]. There are no studies assessing, the role of calcium channel blockers in patients with CKD and ACS. Second generation dihydropyridine calcium channel blockers may be safely used to treat chronic stable angina pectoris in patients with CKD [51, 53]. Diltiazem and verapamil may be used in such patients in the absence of moderate to severe left ventricular systolic dysfunction.

Ranolazine blocks inward sodium channels and has been shown to reduce the frequency of stable angina pectoris in patients with chronic CHD with no effect on hemodynamics [54, 55]. The drug is 70% cleared by the kidney [54]. In the MERLIN TIMI-36 trial, it failed to reduce cardiovascular events in patients with NSTEMI [55]. It may be considered as a fourth line drug for chronic stable angina pectoris with dose modification in patients with CKD.

Renin-Angiotensin-Aldosterone System Blockers

Current guidelines recommend the use of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB’s) in patients in the general population in patients who have suffered STEMI or NSTEMI and whose left ventricular ejection fraction is <40% [21, 22]. These agents have been shown to reduce CV morbidity and mortality in such patients. The role of ACE inhibitors and ARB’s in patients with chronic CHD and normal or near-normal left ventricular systolic function is less well-established, with some studies showing improved cardiovascular outcomes and others failing to do so [56-65]. ACE inhibitors and ARB’s are generally well-tolerated in patients with CKD, but concern exists about their use in ESRD and particularly in HD patients [56-65]. Some trials have shown little or no hyperkalemia and hypotension, while others have demonstrated an increased incidence of hyperkalemia. A retrospective analysis of 126 HD patients showed that the use ACE inhibitors were associated a 52% improvement in survival (RR:0.482,CI:0.2-0.91) [60]. In the FOSDIAL trial 397 patients receiving HD were randomized to receive either fosinopril or placebo. There was a trend towards improved survival after two years (RR: 0.79, CI: 0.59-1.1, p= 0.099) [57]. In a trial of 366 HD patients randomly assigned to receive either an ARB or placebo, the use of an ARB reduced the composite endpoint CV death and specific CVD events (HR: 0.51, 95% CI: 0.33-0.79, p<0.002). In a study of 80 HD patients randomized to receive either candesartan or placebo, candesartan significantly reduced non-fatal CV events (45.9% vs. 16.3%) and mortality (18.9% vs 0%) [63]. Data are sparse concerning the role of combined ACE inhibitor and ARB therapy in advanced CKD. In the VA NEPHRON and ONTARGET trials combination therapy was associated with an increase in adverse events including acute kidney injury, hyperkalemia and death [64, 65].

The efficacy and safety of aldosterone receptor blockers and direct renin inhibitors has not been firmly established in patients with advanced CKD [66-69]. Several small studies have shown the aldosterone receptor blockers may be safe in HD patients with close monitoring of serum potassium levels. In a recent trial of 309 HD patients, 157 received spironolactone. There was a significant reduction in death and hospitalization for CV causes in this study (HR: 0.379, CI: 0.173-0.832, p=0.016) [69].

The preponderance of evidence suggests that ACE inhibitors and ARB’s may reduce CV morbidity and mortality in advanced CKD. There is insufficient evidence thus far concerning the effect of aldosterone receptor blockers and direct renin inhibitors on cardiovascular morbidity and mortality to recommend their routine use for this purpose in such patients.

Lipid Modification Therapy

Multiple randomized clinical trials have demonstrated that statins are capable of significantly reducing CV morbidity and mortality in the general populations. These observations apply to both primary prevention and secondary prevention populations. Such benefits have not been demonstrated in patients receiving HD [70-75].

Three large randomized clinical trials have studied the effects of various lipid modification drugs on CV outcomes in patients with CKD. The 4D (Deutsche Diabetes Dialyse) study randomized 1255 HD patients with diabetes mellitus to receive either atorvastatin 20 mg per day or placebo [72]. Patients were followed for a median of four years. The pri-
primary endpoint was CV death, non-fatal myocardial infarction or non-fatal stroke. The study showed no significant difference in the primary endpoint at six years. However, in patients whose LDL cholesterol was ≥145 mg/dl (highest LDL quartile) atorvastatin therapy was associated with a significantly lower cumulative incidence of the primary endpoint, death from cardiac causes, sudden death, non-fatal myocardial infarction and all cardiac events. The AURORA trial randomized 2,776 HD patients to receive either rosuvastatin 10 mg per day or placebo [73]. The primary composite endpoint was CV death, non-fatal myocardial infarction or non-fatal stroke. There was no significant difference in the cumulative incidence of the primary endpoint at five years between rosuvastatin and placebo-treated patients. However, patients on HD with diabetes mellitus in the AURORA trial appeared to benefit from rosuvastatin therapy HR: 0.08, 95% CI: 0.51-0.90. The SHARP trial randomized 9,000 patients with CKD (including 3,023 on maintenance dialysis) to receive either simvastatin 20 mg and ezetimibe 10 mg or placebo [74]. Patients were followed for a median of 4.9 years. There was a significant reduction of the cumulative incidence of first major atherosclerotic vascular event at five years (risk reduction: 17%, 95%, CI: 0.06-0.26, p = 0.0021) favoring simvastatin/ezetimibe with the curves beginning to diverge at one year. A subgroup analysis of the SHARP trial demonstrated significant reductions non-hemorrhagic stroke, any revascularization and major atherosclerotic events, but not in major coronary events [74].

It is uncertain why statins are less effective in reducing CV events in HD patients than in the general population. Explanations include the possibility that greater inflammation exists in HD patients that cannot be overcome by statin therapy, no effect on electrolyte-related arrhythmias and reduced nitric oxide production which may interfere with the pleiotropic effects of statins. The 2013 KDIGO guidelines did not recommend beginning statin therapy in HD patients despite the high CV risk, but do suggest continuation of statin therapy of patients already receiving it prior to initiation of HD [76-78]. Guidelines for management of dyslipidemia in the general population may be applied to patients with CKD not receiving HD.

MYOCARDIAL REvascularization

Myocardial revascularization may be achieved by surgical means or percutaneous coronary intervention (PCI). In the general population aortocoronary bypass, also known as coronary artery bypass grafting (CABG) is performed primarily in patients with multi-vessel coronary artery disease, particularly in those with high-grade proximal stenoses and/or severe left main stenosis. Prior studies have demonstrated that CABG is superior to medical therapy in patients with significant triple vessel coronary artery disease and moderate to severe left ventricular systolic dysfunction as well as in those with left main stenosis ≥50%. Advanced CKD is a major risk factor in patients undergoing CABG. PCI refers to catheter-based procedures that restore blood flow to ischemic segments of myocardium. Percutaneous transmural coronary angioplasty, while still performed, has largely been replaced by primary stenting with either drug-eluting or bare metal stents. Rotational coronary atherectomy is rarely performed [21]. In patients with CKD, PCI engenders a risk for contrast-induced acute kidney injury. This risk is heightened by the presence of diabetes mellitus and heart failure, two co-morbidities that are commonly present in patients undergoing PCI [21].

In the general population PCI is favored over medical therapy in the management of STEMI (if it can be provided within 90 minutes of the onset of chest pain) and in intermediate to high-risk patients with non-ST segment ACS [21, 22]. CABG in such circumstances is reserved for those with ongoing ischemia despite PCI, failed PCI and patients with severe triple vessel disease and/or left main stenosis. PCI is increasingly employed for myocardial revascularization in patients with chronic CHD in the general population, even in those with multi-vessel coronary artery disease.

CKD, particularly advanced CKD, appears to increase CV risk in patients with acute myocardial infarction [79]. Charytan et al. reported that patients with acute myocardial infarction and concomitant CKD had more proximal and longer culprit lesions [80]. In a subset of the VALIANT trial Anakevar and colleagues reported that each ml/m² decrease in eGFR below 81 ml/min/1.73m² was independently associated with increased risk of non-fatal cardiovascular events and death (HR: 1.10, 95% CI: 1.08-1.12) [79]. Current guidelines recommend primary PCI in all patients with acute STEMI regardless of renal function if the intervention can be performed within 90 minutes of the onset of chest pain. PCI is also recommended in STEMI patients with CKD with evidence of ongoing myocardial ischemia <12 hours in duration [22]. Current guidelines suggest that there is insufficient evidence for or against an early invasive strategy for patients with advanced CKD in patients with non-ST segment ACS [21]. The SWEDEHEART registry of 23,262 consecutive patients with NSTEMI assessed the effect of early revascularization (within 14 days) by either PCI or CABG in patients with CKD [81]. In patients with stage 3 CKD one year mortality in the overall study population was 36% lower with early revascularization compared to those treated medically (HR: 0.64; 95% CI: 0.56 to 0.73; p<0.001). The benefit of an early invasive approach was not evident in patients receiving HD (44% versus 53%; HR: 1.61; 95% CI: 0.84 to 3.09; p=0.150). One-year follow-up after PCI in a cohort of 27 HD patients and 250 non-HD patients showed that cardiac death was more frequent in dialysis patients. In a meta-analysis of seven studies enrolling 23,234 patients 6276 who received early revascularization were compared to 16,958 who received initial medical therapy [82]. Patients with ESRD, were observed to have a 40% reduction in the odds of one-year mortality; however the magnitude of the reduction in mortality with early revascularization diminished with greater severity of CKD.

More information is available concerning the effects of PCI and CABG on CV outcomes in patients with CKD and chronic CHD. In the APPROACH trial three categories of renal function were identified: dialysis-dependent kidney disease (n=662), non-dialysis-dependent kidney disease (n=750) and a reference group (serum creatinine < 2.3 mg/dl, n=40,379) [83]. Survival was assessed in subgroups receiving CABG, PCI or no revascularization. The adjusted 8-year survival rates for CABG and PCI were significantly higher in the HD group for those receiving CABG (44.8%) or PCI
Patients with CKD, particularly those with ESRD who receive dialysis are at high risk for CHD. Therapeutic options that are effective in patients with CHD in the general population may be less so in patients with advanced CKD. In some cases drugs used to treat ACS and chronic CHD may require dose adjustments due to reduced renal clearance. CAGB is associated with higher in-hospital mortality, but lower long-term risk for MACE compared to PCI in patients with advanced CKD, including those receiving HD. In most studies, DES use reduced the risk for MACE compared to BMS use with the possible exception of sirolimus-eluting stents. There are no studies involving the use of second and third generation DES in particular with advanced CKD.

CONCLUSION

Patients with CKD, particularly those with ESRD who receive dialysis are at high risk for CHD. Therapeutic options that are effective in patients with CHD in the general population may be less so in patients with advanced CKD. In some cases drugs used to treat ACS and chronic CHD may require dose adjustments due to reduced renal clearance. CAGB is associated with higher in-hospital mortality than PCI, but better long-term CV outcomes. Because of variability in the severity of CHD and CKD, therapeutic decisions regarding patients with CKD and CHD must be individualized and guided by symptoms and long-term prognosis.
CONFLICT OF INTEREST
The authors confirm that this article content has no conflicts of interest.

ACKNOWLEDGEMENTS
Declared none.

REFERENCES
[1] U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2013.
[2] Levey AS, de Jong PE, Coresh J, et al. Definition and classification of chronic kidney disease; a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67(6): 2089-100.
[3] Weiner D, Tabatabaies E, Tighiouart H, et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 2006; 48(3): 392-401.
[4] Sarnak MS, Coronado BE, Greene T, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002; 57(5): 327-35.
[5] Goldsmith DJ, Covic A. Coronary artery disease in uremia: Etiology, diagnosis, and therapy. Kidney Int 2001; 60(6): 2059-78.
[6] Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351(10): 1296-305.
[7] Coresh J, Longnecker JC, Miller ER 3rd, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1999; 9(12 Suppl): S24-30.
[8] Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116(1): 85-97.
[9] Cheung AK, Sannak MJ, Yan G, et al. Cardiovascular disease in maintenance hemodialysis patients. Kidney Int 2004; 65: 2380-9.
[10] U.S. Renal Data System, USRDS 2002-2013 Annual Data Reports: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, 2002-2013.
[11] Parekh RS, Zhang L, Fivush BA, Klag MJ. Incidence of an atheroiskemic syndrome by race in the Dialysis and Mortality Study – a sample of the CUS ESRD population. J Am Soc Nephrol 2005; 16: 1420-6.
[12] Ohtake T, Kobayashi S, Moriya H, et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol 2005; 16: 1441-8.
[13] Charytan D, Kuntz RE, Mauri L, DeFilippis C. Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007; 49: 409-16.
[14] Conlon PJ, Krucoff MW, Minda S, Schumm D, Schwab SJ. Incidence and long-term significance of transient ST segment deviation in hemodialysis patients. Clin Nephrol 1998; 44: 155-61.
[15] Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606-15.
[16] U.S. Renal Data System. The USRDS Dialysis Mortality and Morbidity Study, Wave 2. Am J Kidney Dis 1997; 30(2 Suppl 1): S67-S85.
[17] Balla S, Nusair MB, Alpert MA, Risk factors for cardiovascular disease in patients with chronic kidney disease. Curr Opin Pharmacol 2013; 13: 192-9.
[18] Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease; comparison of traditional and novel risk factors. JAMA 2005; 293: 1737-45.
[19] Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17(7): 2034-47.
[20] Jaki N, Hase H, Nakamura R, Yamaguchi T. Onset of coronary artery disease prior to initiation of haemodialysis in patients with end-stage renal disease. Nephrol Dial Transplant 1997; 12: 718-23.
[21] Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61(23): e179-347.
[22] American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 2013; 82(1): E1-27.
[23] Sarnak MS, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease. Circulation 2003; 108: 2154-69.
[24] K/DOQI Workgroup, K.D., K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45(4 Suppl 3): S1-153.
[25] Coats WC, Baig SZ, Alpert MA, Aggarwal K. Management of coronary artery disease in patients with chronic kidney disease. Adv Perit Dial 2009; 25: 125-8.
[26] Herzog CA. How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol 2003; 14(10): 2556-72.
[27] Herzog CA, MA JL, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339(12): 799-805.
[28] Gloreux G, Cohen G, Jankowski J, Vanderheer R, Platelet-Leukocyte activation, inflammation, and uremia. Semin Dial 2009; 22(4): 423-7.
[29] Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis. JAMA 2001; 286(10): 1187-94.
[30] Jardine MJ, Nininova T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol 2010; 56(12): 956-65.
[31] Palmer SC, DiMicco L, Razavian M, et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2013; 2: CD008834.
[32] Cusset T, Fieri C, Moro PJ, et al. Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after acute coronary syndrome. Thromb Res 2010; 126(5): e400-2.
[33] Morel O, El Ghanmi S, Jesel L, et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y inhibition by clopidogrel. J Am Cardiol 2011; 57(4): 399-408.
[34] Best PJ, Steinburg SW, Berger PB, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. AM Heart J 2008; 155(4): 687-93.
[35] Small DS, Wurisho RE, Ernest CS 2nd, et al. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. J Clin Pharmac Ther 2009; 34(5): 585-94.
[36] James S, Budai A, Aylward A, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010; 122(11): 1056-67.
[37] Wallentin L, Becker RC, Budai A, et al. Ticagrelor versus clopido- dogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361(11): 1045-57.
[38] Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Acute Myocardial Infarction. Lancet 1999; 354: 1757-62.
[39] Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. CTET Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999; 340(21): 1623-9.
[40] Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA. Influence of concurrent renal dysfunction on outcomes
of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003; 41(5): 718-24.

[41] Tsai TT, Maddox TM, Roe MT, et al. Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA 2009; 302(22): 2458-64.

[42] Harrington RA, Becker RC, Ezekowicz, et al. Antiplatelet therapy, for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(suppl): 670S-707S.

[43] Göppel GH, Pickworth KK, Seth SK, Tanna SB, Barnes JF. Exonaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000; 20(7): 771-5.

[44] Thorevska N, Amoateng-Adjepong Y, Sabahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004; 125(3): 856-63.

[45] Achardji S, Baber U, Mehran R, et al. Prognostic significance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney disease treated with different antiplatelet regimens: a sub-study from the ACUITY trial. Circ Cardiovasc Interv 2012; 5(2): 157-65.

[46] Stangier J, Rathgen K, Hawley CM, et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol 2011; 58(11): 1152-61.

[47] Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, double-blind, phase II trial. Lancet 2009; 374: 29-38.

[48] APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention on Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119(22): 2877-85.

[49] Badve SV, Roberts MA, Hawley CM, et al. The effects of statins on mortality and cardiovascular events in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003; 42(2): 201-8.

[50] Inrig JK. Antiangiogenic agents in hemodialysis patients: a current perspective. Semin Dial 2010; 23(3): 290-7.

[51] Agarwal R. Supervised atenolol therapy in the management of heart failure. Clin Pharmacokinet 2008; 47(5): 299-309.

[52] Morrow DA, Scirica BM, Karwatskowa-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA 2007; 297(16): 1775-83.

[53] Han SW, Won YW, Yi JH, Kim HJ. No impact of hyperkalaemia with renin-angiotensin system blockade in maintenance haemodialysis patients. Nephrol Dial Transplant 2007; 22(4): 1170-5.

[54] Zannad F, Kessler M, Lehert P, et al. Anitcoagulant therapy for non-ST-segment elevation acute coronary syndromes: the MERLIN-TIMI 36 study. N Engl J Med 2004; 351(13): 1285-95.

[55] Knoll GA, Saghal A, Nair RC, Graham J, Van Wakaren C, Burns KD. Renin-angiotensin system blockade and the risk of hyperkalaemia in chronic hemodialysis patients. Am J Med 2002; 12(2): 110-4.

[56] Efrati S, Zaldenstein R, Dishy V, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002; 40(5): 1023-9.
[83] APPROACH Investigators. Survival after coronary revascularization among patients with kidney disease. Circulation 2004; 110(14): 1890-5.

[84] Szczec LA, Reddan DN, Owen WF, et al. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int 2001; 60(1): 292-9.

[85] Manabe S, Shimokawa T, Fukui T, et al. Coronary artery bypass surgery versus percutaneous coronary artery intervention in patients on chronic hemodialysis: does a drug-eluting stent have an impact on clinical outcome? J Card Surg 2009; 24(3): 234-9.

[86] Sunagawa G, Komiya T, Tamura N, Sakaguchi G, Kobayashi T, Murashita T. Coronary artery bypass surgery is superior or percutaneous coronary intervention with drug-eluting stents for patients with chronic renal failure on hemodialysis. Ann Thorac Surg 2010; 89(6): 1896-900.

[87] Reddan DN, Szczec LA, Tuttle RH, et al. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. Am Soc Nephrol 2003; 14(9): 2373-80.

[88] Rinehart AL, Herzog CA, Collins AJ, Flack JM, MA JL, Opsahl JA. A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients. Am J Kidney Dis 1995; 25(2): 281-90.

[89] Crawford FA Jr, Selby JH Jr, Bower JD, Lehan PH. Coronary revascularization in patients maintained on chronic hemodialysis. Circulation 1977; 56(4 Pt 1): 684-7.

[90] Agirbasli M, Weintraub WS, Chang GL, et al. Outcome of coronary revascularization in patients on renal dialysis. Am J Cardiol 2000; 86(4): 395-9.

[91] Zheng H, Xue S, Lian F, Huang RT, Wang YY. Meta-analysis of clinical studies comparing coronary artery bypass grafting with percutaneous coronary intervention in patients with end-stage renal disease. Eur J Cardiothorac Surg 2013; 43(3): 459-67.

[92] Opsahl JA, Husebye DG, Helseth HK, Collins AJ. Coronary artery bypass surgery in patients on maintenance dialysis: long-term survival. Am J Kidney Dis 1988; 12(4): 271-4.

[93] Gruberg L, Dangas G, Mehran R, et al. Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure. Catheter Cardiovasc Interv 2002; 55(1): 66-72.

[94] Le Feuvre C, Dambry G, Hefti G, et al. Comparison of clinical outcome following coronary stenting or balloon angioplasty in dialysis versus non-dialysis patients. Am J Cardiol 2000; 85(11): 1365-8.

[95] Kuchulakanti PK, Torguson BS, Chu WW, et al. Impact of chronic renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary intervention with sirolimus-eluting stents versus bare metal stents. Am J Cardiol 2006; 97(6): 792-7.

[96] Tsai TT, Messinger JC, Brennan JM, et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry–CMS claims database. J Am Coll Cardiol 2001; 58(18): 1859-69.

[97] Das P, Moliterno DJ, Charnigo R, et al. Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. J Invasive Cardiol 2006; 18(9): 405-8.

[98] Yachi S, Tanabe K, Tanimoto S, et al. Clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents versus bare-metal stents in hemodialysis patients. Am J Kidney Dis 2009; 54(2): 299-306.

[99] Jeong YH, Hong MK, Lee CW, et al. Effect of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation. Int J Cardiol 2008; 125(1): 36-40.

[100] Halkin A, Selzer F, Marroquin O, Laskey W, Detre K, Cohen H. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients. J Invasive Cardiol 2006; 18(12): 577-83.

[101] Nakazawa G, Tanabe K, Aoki J, et al. Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents. Catheter Cardiovasc Interv 2007; 69(6): 804-14.

[102] Aoyama T, Ishii H, Toriyama T, et al. Sirolimus-eluting stents vs bare metal stents for coronary artery disease in Japanese patients with renal failure on hemodialysis. Circ J 2008; 72(1): 56-60.

[103] Ishii N, Kobayashi Y, Takebayashi H, et al. Impact of drug-eluting stents on clinical and angiographic outcomes in dialysis patients. Circ J 2007; 71(10): 1525-9.

[104] Mishkel GJ, Varghese JJ, Moore AL, Agguire F, Markwell SJ, Shelton M. Short- and long-term clinical outcomes of coronary drug-eluting stent recipients presenting with chronic renal disease. J Invasive Cardiol 2007; 19(8): 331-7.

[105] Ota T, Umeda H, Yokota S, et al. Clinical outcomes following percutaneous coronary intervention with sirolimus-eluting stents in hemodialysis patients. Am J Cardiol 2009; 103(14): 92-8.

[106] Rosemblum MA, Rogging MJ, Farkouh ME, Winston JA, Kim MC. Diminished benefits of drug-eluting stents versus bare metal stents in patients with severe renal insufficiency. Nephron Clin Pract 2009; 113(3): 198-202.